TapewireFind a company

person · Reporting owner

Mehta Kishan

Disclosed activity across 7 companies

Tapewire entity
50611
SEC CIK
0001850520

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Akili, Inc.AKLI · Entity 89130Former Director and 10% OwnerAugust 19, 2022August 23, 2022
Benitec Biopharma Inc.BNTC · Entity 5596DirectorDecember 01, 2025December 03, 2025
Biohaven Ltd.BHVN · Entity 4379DirectorApril 28, 2026May 01, 2026
Biohaven Pharmaceutical Holding Co Ltd.BHVN · Entity 123269DirectorOctober 03, 2022October 03, 2022
Social Capital Suvretta Holdings Corp. IIDNAB · Entity 125597Director · President · 10% ownerAugust 16, 2021August 16, 2021
Social Capital Suvretta Holdings Corp. IVDNAD · Entity 123913Director · President · 10% ownerAugust 16, 2021August 16, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Akili, Inc.

Report date August 19, 2022 · Filed August 23, 2022

Jointly reported with SCS Sponsor I LLC, Cowen Aaron, ChaChaCha DNA I, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect6,860,000 Reported balance After 2022-08-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-08-19 · Exercise / conversion · Acquired 6,220,000 · Balance 6,860,000

F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination").

F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-08-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2022-08-19 · Other · Disposed 6,860,000 · Balance 0

F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests.

Class B ordinary sharesSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-08-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-08-19 · Exercise / conversion · Disposed 6,220,000 · Balance 0

F4: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination.

F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination").

F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

Filing footnotes · ownership attribution and instrument terms

F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination").

F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests.

F4: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination.

Benitec Biopharma Inc.

Report date December 01, 2025 · Filed December 03, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.23 · Expires 2035-12-01Direct35,000 Reported balance After 2025-12-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-12-01 · Grant · Acquired 35,000 · Balance 35,000

F1: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service.

F2: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service.

F2: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

Biohaven Ltd.

Report date April 28, 2026 · Filed May 01, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2036-04-28Direct68,693 Reported balance After 2026-04-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-04-28 · Grant · Acquired 68,693 · Balance 68,693

F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Biohaven Pharmaceutical Holding Co Ltd.

Report date October 03, 2022 · Filed October 03, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect0 Reported balance After 2022-10-03 transaction · row 1
1 source row

Row 1 · 2022-10-03 · Disposition to issuer · Disposed 10,640 · Balance 0

F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").

Restricted Share Unit AwardSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-10-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2022-10-03 · Disposition to issuer · Disposed 1,875 · Balance 0

F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.33 · Expires 2032-04-28Direct0 Reported balance After 2022-10-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-10-03 · Disposition to issuer · Disposed 8,239 · Balance 0

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.91 · Expires 2031-06-15Direct0 Reported balance After 2022-10-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2022-10-03 · Disposition to issuer · Disposed 13,004 · Balance 0

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.85 · Expires 2029-12-18Direct0 Reported balance After 2022-10-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2022-10-03 · Disposition to issuer · Disposed 15,000 · Balance 0

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.64 · Expires 2029-01-17Direct0 Reported balance After 2022-10-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2022-10-03 · Disposition to issuer · Disposed 20,000 · Balance 0

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").

F3: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F4: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Social Capital Suvretta Holdings Corp. II

Report date August 16, 2021 · Filed August 16, 2021

Jointly reported with SCS Sponsor II LLC, Palihapitiya Chamath, Cowen Aaron, ChaChaCha DNA II, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B ordinary sharesSEC Table II · derivative / convertible securityDirect6,220,000 Reported balance After 2021-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-08-16 · Disposition to issuer · Disposed 75,000 · Balance 6,220,000

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F3: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F3: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Social Capital Suvretta Holdings Corp. IV

Report date August 16, 2021 · Filed August 16, 2021

Jointly reported with SCS Sponsor IV LLC, Palihapitiya Chamath, Cowen Aaron, ChaChaCha DNA IV, LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class B ordinary sharesSEC Table II · derivative / convertible securityDirect6,220,000 Reported balance After 2021-08-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2021-08-16 · Disposition to issuer · Disposed 75,000 · Balance 6,220,000

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F3: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F3: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PROKIDNEY CORP.

Report date July 11, 2022 · Filed July 13, 2022

Jointly reported with SCS Sponsor III LLC, Cowen Aaron, ChaChaCha DNA III, LLC

Section 16 reporting ended · disclosed 2022-07-13. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A ordinary sharesSEC Table I · non-derivativeDirect6,860,000 Reported balance After 2022-07-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-07-11 · Exercise / conversion · Acquired 6,220,000 · Balance 6,860,000

F1: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP.

F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

Class A ordinary sharesSEC Table I · non-derivativeDirect0 Reported balance After 2022-07-11 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2022-07-11 · Other · Disposed 6,860,000 · Balance 0

F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 Class A ordinary shares to its members pro rata in accordance with their respective interests.

Class B ordinary sharesSEC Table II · derivative / convertible securityDirect0 Reported balance After 2022-07-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2022-07-11 · Exercise / conversion · Disposed 6,220,000 · Balance 0

F4: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date.

F1: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP.

F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

Filing footnotes · ownership attribution and instrument terms

F1: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP.

F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 Class A ordinary shares to its members pro rata in accordance with their respective interests.

F4: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 28, 2026 Filed May 1, 2026 00:09 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Options (Right to buy) · Derivative 68,693 $0.00 Strike: $9.61 $0.00
Disclosure

SEC source: 0001850520-26-000005 · wk-form4_1777594180.xml · derivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,693

Underlying: Common Shares · 68,693 shares

Expires 2036-04-28

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2027 or (b) the date of the 2027 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
March 17, 2026 Filed Mar 19, 2026 22:17 UTC Biohaven Ltd. BHVN · Entity 4379 GiftCommon Shares 17,342 $0.00 $0.00
Disclosure

SEC source: 0001850520-26-000003 · wk-form4_1773958666.xml · nonDerivative · entry 2

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kishen Mehta 21 Family Irrevocable Trust

Disclosed balance after: 17,342

F1 · ownership.nature: These Common Shares are held in a trust for the benefit of the Reporting Person's family members, excluding the Reporting Person. The Reporting Person's spouse and the spouse's sibling are co-trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the inclusion of the securities held by the trust in this report and prior Section 16 filings by the Reporting Person is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Read SEC document
March 17, 2026 Filed Mar 19, 2026 22:17 UTC Biohaven Ltd. BHVN · Entity 4379 GiftCommon Shares 17,342 $0.00 $0.00
Disclosure

SEC source: 0001850520-26-000003 · wk-form4_1773958666.xml · nonDerivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,320

Read SEC document
December 01, 2025 Filed Dec 3, 2025 16:19 UTC Benitec Biopharma Inc. BNTC · Entity 5596 GrantOptions (right to buy) · Derivative 35,000 $0.00 Strike: $12.23 $0.00
Disclosure

SEC source: 0001012975-25-000850 · form4.xml · derivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2035-12-01

F1 · shares: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service.

F2 · derivative.exercise_date: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

Read SEC document
May 05, 2025 Filed May 7, 2025 21:13 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Options (Right to buy) · Derivative 31,716 $0.00 Strike: $22.62 $0.00
Disclosure

SEC source: 0001935979-25-000044 · wk-form4_1746652427.xml · derivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,716

Underlying: Common Shares · 31,716 shares

Expires 2035-05-05

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 5, 2026 or (b) the date of the 2026 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
December 09, 2024 Filed Dec 11, 2024 18:48 UTC Benitec Biopharma Inc. BNTC · Entity 5596 GrantOptions (right to buy) · Derivative 35,000 $0.00 Strike: $12.18 $0.00
Disclosure

SEC source: 0001062993-24-020503 · form4.xml · derivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2034-12-09

F1 · shares: Consists of options to purchase shares of the Issuer's common stock awarded to Mr. Mehta in connection with his role as a member of the Issuer's Board of Directors. Mr. Mehta, as Portfolio Manager for Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd (the "Funds") is holding such options for the benefit of the Funds, and as such Mr. Mehta disclaims beneficial ownership of such options. The Funds, and Suvretta Capital Management, LLC ("Suvretta Capital"), the investment manager of the Funds, may be deemed to have an indirect pecuniary interest in such options because Suvretta Capital has rights to receive the benefit of director compensation provided in respect of Mr. Mehta's board service.

F2 · derivative.exercise_date: The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 9, 2025.

Read SEC document
April 30, 2024 Filed May 2, 2024 23:34 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Option (Right to Buy) · Derivative 16,592 $0.00 Strike: $38.80 $0.00
Disclosure

SEC source: 0001562180-24-003755 · primarydocument.xml · derivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,592

Underlying: Common Shares · 16,592 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2025 or (b) the date of the 2025 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
May 02, 2023 Filed May 4, 2023 21:52 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Option (Right to Buy) · Derivative 52,906 $0.00 Strike: $13.20 $0.00
Disclosure

SEC source: 0001562180-23-003945 · primarydocument.xml · derivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,906

Underlying: Common Shares · 52,906 shares

Expires 2033-05-02

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 2, 2024 or (b) the date of the 2024 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:27 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerStock Options (Right to Buy) · Derivative 20,000 Not disclosed Strike: $36.64 Not disclosed
Disclosure

SEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 6

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 20,000 shares

Expires 2029-01-17

F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:27 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerStock Options (Right to Buy) · Derivative 15,000 Not disclosed Strike: $50.85 Not disclosed
Disclosure

SEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 5

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 15,000 shares

Expires 2029-12-18

F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:27 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerStock Options (Right to Buy) · Derivative 13,004 Not disclosed Strike: $90.91 Not disclosed
Disclosure

SEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 4

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 13,004 shares

Expires 2031-06-15

F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:27 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerStock Options (Right to Buy) · Derivative 8,239 Not disclosed Strike: $95.33 Not disclosed
Disclosure

SEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 3

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 8,239 shares

Expires 2032-04-28

F4 · derivative.exercise_price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · shares: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · price: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.exercise_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

F4 · derivative.expiration_date: In connection with the Distribution, each outstanding option to purchase common shares of the Issuer was adjusted such that such option became an option to acquire SpinCo common shares and an option to acquire Common Shares (each such option, a "Post-Spin Issuer Option"). At the effective time of the Merger, each outstanding Post-Spin Issuer Option was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price per Common Share of such Post-Spin Issuer Option and (ii) the number of Common Shares subject to such Post-Spin Issuer Option, less any withholding taxes.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:27 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerRestricted Share Unit Award · Derivative 1,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001562180-22-006958 · primarydocument.xml · derivative · entry 2

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 1,875 shares

Expires not disclosed

F3 · derivative.exercise_price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F3 · shares: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F3 · price: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F3 · derivative.exercise_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

F3 · derivative.expiration_date: In connection with the distribution ("Distribution") by the Issuer to holders of its common shares of all the outstanding common shares of Biohaven Ltd. ("SpinCo"), each outstanding restricted share unit of the Issuer was adjusted such that such restricted share unit became a restricted share unit in respect of common shares of SpinCo and a restricted share unit in respect of Common Shares (each such restricted share unit, a "Post-Spin Issuer RSU"). At the effective time of the Merger, each outstanding Post-Spin Issuer RSU was automatically cancelled in exchange for the right to receive (without interest) an amount in cash equal to the product of (i) the number of Common Shares subject to such Post-Spin Issuer RSU, with any performance conditions applicable to such Post-Spin Issuer RSU deemed achieved at 100%, and (ii) the Merger Consideration, less any withholding taxes.

Read SEC document
October 03, 2022 Filed Oct 3, 2022 20:27 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Disposition to issuerCommon Shares 10,640 $148.50 $1,580,040.00
Disclosure

SEC source: 0001562180-22-006958 · primarydocument.xml · nonDerivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Under the Agreement and Plan of Merger, dated as of May 9, 2022 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Pfizer") and a wholly owned subsidiary of Pfizer ("Merger Sub"), following satisfaction or waiver of the closing conditions set forth in the Merger Agreement, on October 3, 2022 Merger Sub merged with and into the Issuer with the Issuer surviving as the surviving company (the "Merger").

F2 · price: In the Merger, each common share of the Issuer (each, a "Common Share") outstanding immediately prior to the effective time of the Merger (other than certain excluded shares pursuant to the terms of the Merger Agreement), was converted into the right to receive the merger consideration in cash of $148.50, without interest, less any withholding taxes (the "Merger Consideration").

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 GrantStock Options (Right to buy) · Derivative 125,000 $0.00 Strike: $7.00 $0.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 16

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Shares · 125,000 shares

Expires 2032-10-04

F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionStock Options (Right to Buy) · Derivative 10,000 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 15

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 10,000 shares

Expires 2029-01-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionStock Options (Right to Buy) · Derivative 7,500 $0.00 Strike: $2.58 $0.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 14

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 7,500 shares

Expires 2029-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionStock Options (Right to Buy) · Derivative 6,502 $0.00 Strike: $4.61 $0.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 13

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 6,502 shares

Expires 2031-06-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionStock Options (Right to Buy) · Derivative 4,119 $0.00 Strike: $4.84 $0.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 12

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 4,119 shares

Expires 2032-04-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 OtherStock Options (Right to Buy) · Derivative 10,000 Not disclosed Strike: $1.86 Not disclosed
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 11

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Shares · 10,000 shares

Expires 2029-01-17

F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 OtherStock Options (Right to Buy) · Derivative 7,500 Not disclosed Strike: $2.58 Not disclosed
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 10

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Shares · 7,500 shares

Expires 2029-12-18

F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 OtherStock Options (Right to Buy) · Derivative 6,502 Not disclosed Strike: $4.61 Not disclosed
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 9

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,502

Underlying: Common Shares · 6,502 shares

Expires 2031-06-15

F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 OtherStock Options (Right to Buy) · Derivative 4,119 Not disclosed Strike: $4.84 Not disclosed
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · derivative · entry 8

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,119

Underlying: Common Shares · 4,119 shares

Expires 2032-04-28

F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 Tax withholdingCommon Shares 11,716 $7.00 $82,012.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 7

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,662

F3 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionCommon Shares 10,000 $1.86 $18,600.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 6

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,378

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionCommon Shares 7,500 $2.58 $19,350.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 5

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,378

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionCommon Shares 6,502 $4.61 $29,974.22
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 4

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,878

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 Exercise / conversionCommon Shares 4,119 $4.84 $19,935.96
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 3

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,376

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 OtherCommon Shares 937 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 2

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,257

F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement.

Read SEC document
October 03, 2022 Filed Oct 5, 2022 21:39 UTC Biohaven Ltd. BHVN · Entity 4379 OtherCommon Shares 5,320 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,320

F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer").

Read SEC document
August 19, 2022 Filed Aug 23, 2022 17:28 UTC Akili, Inc. AKLI · Entity 89130 Exercise / conversionClass B ordinary shares · Derivative 6,220,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-047241 · doc4.xml · derivative · entry 3

SCS Sponsor I LLC · CIK 0001850369 · Former Director and 10% Owner

Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner

Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner

ChaChaCha DNA I, LLC · CIK 0001869714 · Former Director and 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A ordinary shares · 6,220,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination.

F4 · derivative.exercise_date: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination.

F4 · derivative.expiration_date: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination.

F1 · ownership.direct: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination").

F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

Read SEC document
August 19, 2022 Filed Aug 23, 2022 17:28 UTC Akili, Inc. AKLI · Entity 89130 OtherCommon Stock 6,860,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-047241 · doc4.xml · nonDerivative · entry 2

SCS Sponsor I LLC · CIK 0001850369 · Former Director and 10% Owner

Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner

Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner

ChaChaCha DNA I, LLC · CIK 0001869714 · Former Director and 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · ownership.direct: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests.

Read SEC document
August 19, 2022 Filed Aug 23, 2022 17:28 UTC Akili, Inc. AKLI · Entity 89130 Exercise / conversionCommon Stock 6,220,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-047241 · doc4.xml · nonDerivative · entry 1

SCS Sponsor I LLC · CIK 0001850369 · Former Director and 10% Owner

Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner

Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner

ChaChaCha DNA I, LLC · CIK 0001869714 · Former Director and 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,860,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination").

F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

Read SEC document
July 11, 2022 Filed Jul 13, 2022 16:25 UTC PROKIDNEY CORP. PROK · Entity 5181 Exercise / conversionClass B ordinary shares · Derivative 6,220,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-042045 · doc4.xml · derivative · entry 3

SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner

Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner

Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner

ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A ordinary shares · 6,220,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date.

F4 · derivative.exercise_date: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date.

F4 · derivative.expiration_date: The Class B ordinary shares were automatically convertible into Class A ordinary shares at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustments, and had no expiration date.

F1 · ownership.direct: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP.

F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

Read SEC document
July 11, 2022 Filed Jul 13, 2022 16:25 UTC PROKIDNEY CORP. PROK · Entity 5181 OtherClass A ordinary shares 6,860,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-042045 · doc4.xml · nonDerivative · entry 2

SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner

Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner

Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner

ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F3 · ownership.direct: Represents the distribution for no consideration by the Sponsor of 6,860,000 Class A ordinary shares to its members pro rata in accordance with their respective interests.

Read SEC document
July 11, 2022 Filed Jul 13, 2022 16:25 UTC PROKIDNEY CORP. PROK · Entity 5181 Exercise / conversionClass A ordinary shares 6,220,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-042045 · doc4.xml · nonDerivative · entry 1

SCS Sponsor III LLC · CIK 0001850379 · Former Director and 10% Owner

Mehta Kishan · CIK 0001850520 · Former Director and 10% Owner

Cowen Aaron · CIK 0001869640 · Former Director and 10% Owner

ChaChaCha DNA III, LLC · CIK 0001869713 · Former Director and 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,860,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.direct: The Class B ordinary shares held by the reporting owner, SCS Sponsor III LLC (the "Sponsor"), converted to Class A ordinary shares on a one-for-one basis upon the consummation of the business combination between the issuer and ProKidney LP.

F2 · ownership.direct: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

Read SEC document
April 28, 2022 Filed Apr 29, 2022 21:04 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GrantStock Option (Right to Buy) · Derivative 8,239 $0.00 Strike: $97.74 $0.00
Disclosure

SEC source: 0001562180-22-003588 · primarydocument.xml · derivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,239

Underlying: Common Shares · 8,239 shares

Expires 2032-04-27

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 28, 2023 or (b) the date of the 2023 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
January 10, 2022 Filed Jan 12, 2022 21:04 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Exercise / conversionRestricted Share Unit Award · Derivative 1,875 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-000436 · primarydocument.xml · derivative · entry 2

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,875

Underlying: Common Shares · 1,875 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted share unit represents the contingent right to receive one common share of the Issuer.

F1 · derivative.exercise_price: Each restricted share unit represents the contingent right to receive one common share of the Issuer.

F1 · price: Each restricted share unit represents the contingent right to receive one common share of the Issuer.

F2 · derivative.exercise_date: The reporting person was granted 7,500 restricted share units on January 8, 2020, vesting in four equal installments on January 8, 2020, 2021, 2022 and 2023, subject to the reporting person's continued service with the Issuer at each vesting date.

F3 · derivative.expiration_date: Not applicable.

Read SEC document
January 10, 2022 Filed Jan 12, 2022 21:04 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 Exercise / conversionCommon Shares 1,875 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-000436 · primarydocument.xml · nonDerivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,640

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 16, 2021 Filed Aug 16, 2021 18:28 UTC Social Capital Suvretta Holdings Corp. II DNAB · Entity 125597 Disposition to issuerClass B ordinary shares · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-051677 · doc4.xml · derivative · entry 1

SCS Sponsor II LLC · CIK 0001850373 · Director · 10% owner

Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner

Mehta Kishan · CIK 0001850520 · Director · President · 10% owner

Cowen Aaron · CIK 0001869640 · 10% owner

ChaChaCha DNA II, LLC · CIK 0001869716 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,220,000

Underlying: Class A ordinary shares · 75,000 shares

Expires not disclosed

F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2 · kind: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F3 · ownership.direct: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Read SEC document
August 16, 2021 Filed Aug 16, 2021 18:31 UTC PROKIDNEY CORP. DNAC · Entity 5181 Disposition to issuerClass B ordinary shares · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-051681 · doc4.xml · derivative · entry 1

SCS Sponsor III LLC · CIK 0001850379 · Director · 10% owner

Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner

Mehta Kishan · CIK 0001850520 · Director · President · 10% owner

Cowen Aaron · CIK 0001869640 · 10% owner

ChaChaCha DNA III, LLC · CIK 0001869713 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,220,000

Underlying: Class A ordinary shares · 75,000 shares

Expires not disclosed

F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2 · kind: On August 16, 2021, SCS Sponsor III LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F3 · ownership.direct: The reporting owner, SCS Sponsor III LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA III, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Read SEC document
August 16, 2021 Filed Aug 16, 2021 18:34 UTC Social Capital Suvretta Holdings Corp. IV DNAD · Entity 123913 Disposition to issuerClass B ordinary shares · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-051683 · doc4.xml · derivative · entry 1

SCS Sponsor IV LLC · CIK 0001850376 · Director · 10% owner

Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner

Mehta Kishan · CIK 0001850520 · Director · President · 10% owner

Cowen Aaron · CIK 0001869640 · 10% owner

ChaChaCha DNA IV, LLC · CIK 0001869773 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,220,000

Underlying: Class A ordinary shares · 75,000 shares

Expires not disclosed

F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2 · kind: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F3 · ownership.direct: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Read SEC document
August 16, 2021 Filed Aug 16, 2021 18:25 UTC Akili, Inc. DNAA · Entity 89130 Disposition to issuerClass B ordinary shares · Derivative 75,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-051674 · doc4.xml · derivative · entry 1

SCS Sponsor I LLC · CIK 0001850369 · Director · 10% owner

Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner

Mehta Kishan · CIK 0001850520 · Director · President · 10% owner

Cowen Aaron · CIK 0001869640 · 10% owner

ChaChaCha DNA I, LLC · CIK 0001869714 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,220,000

Underlying: Class A ordinary shares · 75,000 shares

Expires not disclosed

F1 · derivative.exercise_price: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F2 · kind: On August 16, 2021, SCS Sponsor I LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.

F1 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F1 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-256723) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.

F3 · ownership.direct: The reporting owner, SCS Sponsor I LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA I, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:47 UTC Social Capital Suvretta Holdings Corp. II DNAB · Entity 125597 GrantClass A ordinary shares 640,000 $10.00 $6,400,000.00
Disclosure

SEC source: 0001209191-21-045951 · doc4.xml · nonDerivative · entry 1

SCS Sponsor II LLC · CIK 0001850373 · Director · 10% owner

Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner

Mehta Kishan · CIK 0001850520 · Director · President · 10% owner

Cowen Aaron · CIK 0001869640 · 10% owner

ChaChaCha DNA II, LLC · CIK 0001869716 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 640,000

F1 · ownership.direct: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:52 UTC PROKIDNEY CORP. DNAC · Entity 5181 GrantClass A ordinary shares 640,000 $10.00 $6,400,000.00
Disclosure

SEC source: 0001209191-21-045953 · doc4.xml · nonDerivative · entry 1

SCS Sponsor III LLC · CIK 0001850379 · Director · 10% owner

Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner

Mehta Kishan · CIK 0001850520 · Director · President · 10% owner

Cowen Aaron · CIK 0001869640 · 10% owner

ChaChaCha DNA III, LLC · CIK 0001869713 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 640,000

F1 · ownership.direct: The reporting owner, SCS Sponsor III LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA III, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:42 UTC Akili, Inc. DNAA · Entity 89130 GrantClass A ordinary shares 640,000 $10.00 $6,400,000.00
Disclosure

SEC source: 0001209191-21-045949 · doc4.xml · nonDerivative · entry 1

SCS Sponsor I LLC · CIK 0001850369 · Director · 10% owner

Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner

Mehta Kishan · CIK 0001850520 · Director · President · 10% owner

Cowen Aaron · CIK 0001869640 · 10% owner

ChaChaCha DNA I, LLC · CIK 0001869714 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 640,000

F1 · ownership.direct: The reporting owner, SCS Sponsor I LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA I, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Read SEC document
July 02, 2021 Filed Jul 7, 2021 20:56 UTC Social Capital Suvretta Holdings Corp. IV DNAD · Entity 123913 GrantClass A ordinary shares 640,000 $10.00 $6,400,000.00
Disclosure

SEC source: 0001209191-21-045954 · doc4.xml · nonDerivative · entry 1

SCS Sponsor IV LLC · CIK 0001850376 · Director · 10% owner

Palihapitiya Chamath · CIK 0001715450 · Director · Chief Executive Officer · 10% owner

Mehta Kishan · CIK 0001850520 · Director · President · 10% owner

Cowen Aaron · CIK 0001869640 · 10% owner

ChaChaCha DNA IV, LLC · CIK 0001869773 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 640,000

F1 · ownership.direct: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.

Read SEC document
June 15, 2021 Filed Jun 17, 2021 21:51 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GrantStock Options (Right to buy) · Derivative 13,004 $0.00 Strike: $93.21 $0.00
Disclosure

SEC source: 0001562180-21-004379 · primarydocument.xml · derivative · entry 1

Mehta Kishan · CIK 0001850520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,004

Underlying: Common Shares · 13,004 shares

Expires 2031-06-15

F1 · derivative.exercise_date: This option grant was made pursuant to the issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on June 15, 2022, 2023, and 2024, subject to the reporting person's continuous service with the issuer at each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.